Abstract
A 61-year-old white man presented with a stenosing tumour of the right colon and a large hepatic metastasis measuring 90 mm in its largest diameter, judged not suitable for immediate resection. He underwent right hemicolectomy and received 12 cycles of treatment with 5-fluorouracil/leucovorin, oxaliplatin and irinotecan (FOLFOXIRI) plus bevacizumab. According to Response Evaluation Criteria in Solid Tumors (RECIST criteria), he achieved a partial response that allowed a secondary radical hepatic resection. Pathologic examination of the liver specimen showed the absence of residual tumour cells: a pathologic complete response (pCR) was achieved. In this case, an intensive up-front treatment (i.e. the combination of FOLFOXIRI plus bevacizumab) produced the pCR of a liver metastasis from colorectal cancer despite its initial large dimension while confirming the possible discrepancy between radiologic assessment and pathological findings.
Keywords: Metastatic colorectal cancer, liver resection, preoperative chemotherapy, bevacizumab, FOLFOXIRI, complete pathologic response.
Clinical Cancer Drugs
Title:Case-Report: Folfoxiri Plus Bevacizumab in “Poor-Risk” Liver-Only Metastatic Colorectal Cancer: Case Report and State-of-the-Art
Volume: 1
Author(s): Lisa Salvatore, Fotios Loupakis, Andrea Ciarlo, Chiara Cremolini, Camilla Comin, Marta Schirripa, Luca Messerini, Federica Marmorino, Carlotta Antoniotti and Alfredo Falcone
Affiliation:
Keywords: Metastatic colorectal cancer, liver resection, preoperative chemotherapy, bevacizumab, FOLFOXIRI, complete pathologic response.
Abstract: A 61-year-old white man presented with a stenosing tumour of the right colon and a large hepatic metastasis measuring 90 mm in its largest diameter, judged not suitable for immediate resection. He underwent right hemicolectomy and received 12 cycles of treatment with 5-fluorouracil/leucovorin, oxaliplatin and irinotecan (FOLFOXIRI) plus bevacizumab. According to Response Evaluation Criteria in Solid Tumors (RECIST criteria), he achieved a partial response that allowed a secondary radical hepatic resection. Pathologic examination of the liver specimen showed the absence of residual tumour cells: a pathologic complete response (pCR) was achieved. In this case, an intensive up-front treatment (i.e. the combination of FOLFOXIRI plus bevacizumab) produced the pCR of a liver metastasis from colorectal cancer despite its initial large dimension while confirming the possible discrepancy between radiologic assessment and pathological findings.
Export Options
About this article
Cite this article as:
Salvatore Lisa, Loupakis Fotios, Ciarlo Andrea, Cremolini Chiara, Comin Camilla, Schirripa Marta, Messerini Luca, Marmorino Federica, Antoniotti Carlotta and Falcone Alfredo, Case-Report: Folfoxiri Plus Bevacizumab in “Poor-Risk” Liver-Only Metastatic Colorectal Cancer: Case Report and State-of-the-Art, Clinical Cancer Drugs 2014; 1 (1) . https://dx.doi.org/10.2174/2212697X0101131204152941
DOI https://dx.doi.org/10.2174/2212697X0101131204152941 |
Print ISSN 2212-697X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-6988 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Multidisciplinary Approach to Rectal Cancer: Are we Ready for Selective Treatment Strategies?
Anti-Cancer Agents in Medicinal Chemistry Non Steroidal Anti-Inflammatory Drug Induced Damage on Lower Gastro-Intestinal Tract: Is There an Involvement of Microbiota?
Current Drug Safety Docking Studies for Multi-Target Drugs
Current Drug Targets Pyruvate Kinase M2: Regulatory Circuits and Potential for Therapeutic Intervention
Current Pharmaceutical Design Repurposing Drugs for Cancer Prevention
Current Topics in Medicinal Chemistry The Effects of Sevoflurane or Remifentanil on the Stress Response to Surgical Stimulus
Current Pharmaceutical Design The Biochemical Parameters and Vitamin D Levels in ICU Patients with Covid-19: A Cross-Sectional Study
Endocrine, Metabolic & Immune Disorders - Drug Targets Q-TOF LC/MS-based Untargeted Metabolomics Approach to Evaluate the Effect of Folate-Conjugated Cyclodextrins on Triple-Negative Breast Cancer Cells
Current Pharmaceutical Analysis Application of Monoclonal Antibodies as Cancer Therapy in Solid Tumors
Current Clinical Pharmacology Small Molecular Inhibitors of p-STAT3: Novel Agents for Treatment of Primary and Metastatic CNS Cancers
Recent Patents on CNS Drug Discovery (Discontinued) Targeted Drug Delivery in Brain Tumors-nanochemistry Applications and Advances
Current Topics in Medicinal Chemistry Targeted – Therapy and Imaging Response: A New Paradigm For Clinical Evaluation?
Reviews on Recent Clinical Trials Chitosan: A Propitious Biopolymer for Drug Delivery
Current Drug Delivery Synthesis and Characterization of a New Benzoindole Derivative with Apoptotic Activity Against Colon Cancer Cells
Current Pharmaceutical Design CDC25A: A Rebel Within the CDC25 Phosphatases Family?
Anti-Cancer Agents in Medicinal Chemistry Detection of EGFR Somatic Mutations in Non-Small Cell Lung Cancer (NSCLC) Using a Novel Mutant-Enriched Liquidchip (MEL) Technology
Current Drug Metabolism Simultaneous Modeling of Antimycobacterial Activities and ADMET Profiles: A Chemoinformatic Approach to Medicinal Chemistry
Current Topics in Medicinal Chemistry TGF-β1 Signalling, Connecting Aberrant Inflammation and Colorectal Tumorigenesis
Current Pharmaceutical Design Modulation of Doxorubicin Mediated Growth Inhibition of Hepatocellular Carcinoma Cells by Platelet Lysates
Anti-Cancer Agents in Medicinal Chemistry Tolerance in Intestinal Inflammation and Cancer
Current Drug Targets